Praxis Precision Medicines Inc
PRAX
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.06B
Close$
$15.87
95.7% downside
Current Fair Value
95.7% downsideOvervalued by 95.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.06 Billion |
|---|---|
| Enterprise Value | $9.58 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-13.48 |
| Beta | 2.76 |
| Outstanding Shares | 29,131,375 |
Return
| Return on Equity | -25.29% |
|---|---|
| Return on Assets | -24.40% |
| Return on Invested Capital | -27.55% |
Valuation & Multiples
| P/E Ratio | -27.86 |
|---|---|
| PEG | -157.35 |
| Price to Sales | - |
| Price to Book Ratio | 8.01 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -25.94 |
| Enterprise Value to Net Income | -29 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-3.67
Average shareholder expectationRevenue Estimate
$1.25 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-3.65
Average shareholder expectationRevenue Estimate
$130,769
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 360.84% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 15.33%▼ 94.74% |
|---|---|
| Total Invested | $1.48B▼ 85.51% |
| Investors Holding | 87▼ 222.00% |
ESG Score
No data
About Praxis Precision Medicines Inc
2,020 employeesPraxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying in...